A Hidden Opportunity - Medicaid's Role in Supporting Equitable Access to Clinical Trials

Affiliations

¹ From the Division of Hematology and Oncology (S.U.T.) and the Department of Internal Medicine (S.U.T., C.E.G.), Perelman School of Medicine, and the Leonard Davis Institute of Health Economics (S.U.T., C.E.G.), University of Pennsylvania, Philadelphia; and the Division of Health Policy and Economics, Department of Population Health Sciences, Weill Medical College, Cornell University, New York (W.L.S.).

Samuel U Takvorian et al. N Engl J Med. 2021.

. 2021 May 27;384(21):1975-1978.

doi: 10.1056/NEJMp2101627. Epub 2021 May 22.

¹ From the Division of Hematology and Oncology (S.U.T.) and the Department of Internal Medicine (S.U.T., C.E.G.), Perelman School of Medicine, and the Leonard Davis Institute of Health Economics (S.U.T., C.E.G.), University of Pennsylvania, Philadelphia; and the Division of Health Policy and Economics, Department of Population Health Sciences, Weill Medical College, Cornell University, New York (W.L.S.).

No abstract available

Figures

1. Duma N, Vera Aguilera J, Paludo J, et al. Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract 2018;14(1):e1–e10. - PubMed
1. Chastain DB, Osae SP, Henao-Martínez AF, Franco-Paredes C, Chastain JS, Young HN. Racial disproportionality in Covid clinical trials. N Engl J Med 2020;383(9):e59. - PubMed
1. Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research participants. Annu Rev Public Health 2006;27:1–28. - PubMed
1. Ghebre RG, Jones LA, Wenzel JA, Martin MY, Durant RW, Ford JG. State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual. Cancer 2014;120:Suppl 7:1122–30. - PMC - PubMed
1. Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 2019;5(10):e191870. - PMC - PubMed